StreetInsider.com News Articles

Form 6-K NovaBridge Biosciences For: Oct 25

Mon, 26 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261026/27230066.html

NovaBridge reports Phase 1b givastomig data at ESMO 2026

Sun, 25 Oct 2026 07:00:19 -0400

NovaBridge Biosciences (Nasdaq: NBP) presented updated results from its ongoing Phase 1b study of givastomig at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, on Oct. 25, 2026.

Givastomig is a CLDN18.2 x 4-1BB bispecific antibody being evaluated in combination with nivolumab and chemotherapy for patients with HER2-negative first-line metastatic gastroesophageal adenocarcinoma. The updated dataset, with a cutoff of Aug. 6, 2026, included 71 patients across the 8 mg/kg and 12 mg/kg dose cohorts.

Among efficacy-evaluable patients treated at the 8 mg/kg dose, the study reported an objective response rate of 79%, a disease control rate of 97%, a

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Sun, 25 Oct 2026 07:00:00 -0400

Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomig
Clinical activity observed across CLDN18.2 expression levels, including in patients with lower-expression tumors not eligible for currently approved CLDN18.2-targeted therapies
Totality of efficacy, safety and long-term follow-up data supports selection of the 8 mg/kg dose for registrational development
Ongoing U.S. Food and Drug Administration (FDA) interactions, Orphan Drug Designation, Fast Track Designation and progress on Phase 3 planning further support a defined path towards registrational development
NovaBridge to host investor webcast on November 2, 2026, to discuss the updated data and registrational development

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Sun, 25 Oct 2026 07:00:00 -0400

Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomig
Clinical activity observed across CLDN18.2 expression levels, including in patients with lower-expression tumors not eligible for currently approved CLDN18.2-targeted therapies
Totality of efficacy, safety and long-term follow-up data supports selection of the 8 mg/kg dose for registrational development
Ongoing U.S. Food and Drug Administration (FDA) interactions, Orphan Drug Designation, Fast Track Designation and progress on Phase 3 planning further support a defined path towards registrational development
NovaBridge to host investor webcast on November 2, 2026, to discuss the updated data and registrational development

Form 6-K NovaBridge Biosciences For: Oct 23

Fri, 23 Oct 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20261023/27225770.html

Visara secures option to acquire YOL104-2 for eye cancer treatment

Tue, 20 Oct 2026 07:00:54 -0400

Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), has entered into an asset purchase option agreement with YOLO Immune to acquire worldwide rights to the YOL104 Program, including the drug candidate YOL104-2, for the treatment of ocular surface squamous neoplasia (OSSN).

YOL104-2 is a bioengineered, trivalent interferon alpha peptibody currently under investigation for OSSN, a condition encompassing cancerous and precancerous growths on the cornea and conjunctiva. There is currently no FDA-approved therapy for the condition.

Under the terms of the agreement, Visara will make an upfront payment to YOLO Immune in exchange for an exclusive option to acquire worldwide

Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia

Tue, 20 Oct 2026 07:00:00 -0400

YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)

Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. (“Visara”), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. ("NovaBridge") (NASDAQ: NBP), today announced that it has entered into an asset purchase option agreement (the “Option Agreement”) with YOLO Immune (“YOLO”). The Option Agreement provides Visara with an exclusive option to acquire worldwide rights to the YOL104 Program and develop

Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia

Tue, 20 Oct 2026 07:00:00 -0400

Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences

Form 4 NovaBridge Biosciences For: Oct 15 Filed by: Woo Ian Ying

Mon, 19 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261019/27204049.html

Visara licenses nerve growth factor therapy for rare eye disease

Tue, 13 Oct 2026 07:02:07 -0400

Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), announced it has entered into an exclusive license agreement with Wuhan Hiteck Biological Pharma Co., Ltd. to develop and commercialize VIS-102, an investigational modified recombinant human nerve growth factor therapy for neurotrophic keratitis.

Under the agreement, Visara receives exclusive worldwide rights, excluding Greater China, to develop and commercialize VIS-102. Hiteck will receive an upfront payment, potential development, regulatory and commercial milestone payments, and tiered royalties on net sales.

Neurotrophic keratitis is a rare degenerative corneal disease caused by impaired sensory innervation that can lead to persistent epithelial defects, corneal ulceration, and

Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China